

Redeye Initiates Coverage of OncoZenge

Redeye initiates coverage of OncoZenge, a Swedish biotech company offering an innovative solution to the USD1.6bn oral mucositis treatment market. Bolstered by a strong ownership, a newly signed commercial partnership, and a de-risked pathway to the market, we see ample upside potential.

[Read more and download the Research Report.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Redeye Initiates Coverage of OncoZenge](#)